Kalaris Therapeutics, Inc.
No enriched coverage for $KLRS in the last 7 days.
No SEC Form 4 filings for $KLRS in the last 30 days.
See all $KLRS insider activity →Kalaris Therapeutics, Inc. (KLRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027 Potential Phase 3 clinical trials remain on track for initiation by year-end 2027 $
Kalaris Therapeutics (NASDAQ:KLRS) shares fell 6.4% on Monday after the company named Liisa Bayko as its new CFO. Bayko has over 20 years in biotech finance, most recently at Evercore ISI. Kalaris said it continues enrolling a Phase 1b/2 study of TH103 for treatment-naïve neovascular age-related macular degeneration.
Kalaris Therapeutics, Inc. (KLRS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 d125092dex101.htm EX-10.1 EX-10.1 EXHIBIT 10.1 Execution Version EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of July 7, 2026 by and between Kalaris Therapeutics, Inc. (the “Company”), and Liisa Bayko (the “Executive”) (together, the “Part
Recent KLRS coverage spans financial news, technology and corporate actions.
The 8-K provides fresh balance-sheet runway guidance and updated TH103 clinical execution milestones, which can shift near-term risk and valuation expectations.
The immediate move is tied to the CFO appointment, but the article provides no new financial guidance or clinical readout.
CFO appointment and disclosed compensation package can shift near-term governance and execution expectations, but no operational or financial guidance is provided.
Expanded early clinical efficacy and pharmacokinetic retention data increase perceived probability of durable dosing, supporting a bullish re-rating into later-stage planning.
Positive expanded Phase 1a results and longer retreatment intervals support a bullish repricing, but near-term conviction depends on Phase 1b/2 loading regimen readouts.
alphai scores every news story that mentions KLRS with an AI model for sentiment and relevance, and aggregates insider trades from Kalaris Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kalaris Therapeutics, Inc. (KLRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027 Potential Phase 3 clinical trials remain on track for initiation by year-end 2027 $
3 min readKalaris Therapeutics (NASDAQ:KLRS) shares fell 6.4% on Monday after the company named Liisa Bayko as its new CFO. Bayko has over 20 years in biotech finance, most recently at Evercore ISI. Kalaris said it continues enrolling a Phase 1b/2 study of TH103 for treatment-naïve neovascular age-related macular degeneration.
4 min readKalaris Therapeutics, Inc. (KLRS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 d125092dex101.htm EX-10.1 EX-10.1 EXHIBIT 10.1 Execution Version EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of July 7, 2026 by and between Kalaris Therapeutics, Inc. (the “Company”), and Liisa Bayko (the “Executive”) (together, the “Part
4 min readKalaris Therapeutics (NASDAQ:KLRS) said expanded Phase 1a data for TH103 in neovascular age-related macular degeneration showed vision and retinal-anatomy improvements, with intraocular retention suggested by plasma pharmacokinetics. The company reported 41% of treatment-naive patients delaying retreatment beyond four months after one injection, and no intraocular inflammation at 2.5 mg. KLRS rose about 18% to $5.43.
4 min readKalaris Therapeutics (NASDAQ:KLRS) shares rose about 29% after Phase 1a results for TH103 in neovascular age-related macular degeneration. The company reported vision and retinal anatomy improvements in expanded cohorts of 20 patients, with no intraocular inflammation at 2.5 mg and one transient case at 5 mg. TH103 showed lower Cmax versus leading anti-VEGF agents and longer retreatment intervals. Phase 1b/2 enrollment is ongoing, with initial data expected in H1 2027.
3 min readKalaris Therapeutics (KLRS) reported expanded Phase 1a data for TH103 in neovascular age-related macular degeneration. The study included 17 treatment-naive and 3 treatment-experienced patients with 6-month follow-up. Plasma Cmax was 27 to 53 times lower than leading anti-VEGF agents, with 29% needing no anti-VEGF during follow-up. Safety showed no IOI at 2.5 mg and one transient IOI at 5 mg.
4 min readKalaris Therapeutics (Nasdaq: KLRS) said it appointed Laurie Keating to its Board of Directors effective Aug. 1, 2026, replacing Morana Jovan-Embiricos, who is stepping down. Keating is chair of PepGen (Nasdaq: PEPG) and a board member of Immuneering (Nasdaq: IMRX). Kalaris is developing TH103 for neovascular AMD.
2 min readKalaris Therapeutics, Inc. (KLRS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001754068 0001754068 2026-07-03 2026-07-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2
2 min readRaymond James has reiterated a "Strong Buy" rating for Kalaris Therapeutics Inc (KLRS) on March 09, 2026, though no new price target was disclosed. This signals continued confidence in Kalaris's prospects despite limited analyst coverage and a modest market reaction of a 1.11% price change since the announcement. Investors are advised to monitor catalysts and the company's financial health, with Meyka AI also grading KLRS with a "B" based on various market factors.
2 min readWall Street Zen has upgraded Kalaris Therapeutics (NASDAQ:KLRS) from a "sell" to a "hold" rating. Despite mixed analyst coverage, the stock holds a "Moderate Buy" consensus rating with a target price of $14.00, driven by several buy ratings. Notably, director Srinivas Akkaraju recently made a significant insider purchase of 479,847 shares totaling $5.0 million, increasing his stake by almost 32%.
3 min read
